Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole for anhedonia and major depression in patients receiving buprenorphine maintenance
IRCT20240905062953N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and persistent depressive disorder (PDD) comparing Pramipexole with Placebo (2 arms). Primary endpoints: Anhedonia and Quality of life. Started Nov 2024; status: completed.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on IRCT20240905062953N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240905062953N1.